AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03042455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo and rTMS
Description: The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
Study NCT03042455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo
Description: The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
Study NCT03042455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
Study NCT03793725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: Anti-PD-1 Antibody
Study NCT03793725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Anti-angiogenic drugs
Study NCT02127996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
Study NCT02127996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline
Study NCT06404593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
Study NCT01075256 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: Placebo toothpaste
Study NCT00800592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 10 mg sildenafil bolus
Study NCT03833635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
Study NCT03833635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: the sham intervention consists in a stable skin-to-skin contact with the participant
Study NCT00639730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: High fat, low carbohydrate diet
Study NCT03717090 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Sample collection study Sample collection and collection of laboratory values
Study NCT01202942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quest
Description: Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
Study NCT01180543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oplon Active Patch
Description: Patches are placed over acne lesion overnight. Treatment is a single treatment.
Study NCT01180543 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: same as active patch
Study NCT00615264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
Study NCT00615264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
Study NCT00969397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antiangiogenic
Description: Topical Antiangiogenic
Study NCT00969397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Description: Pulsed Dye Laser
Study NCT00058422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Study NCT00058422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00058422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00058422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00058422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00058422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00058422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00058422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Study NCT00058422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT01839422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
Study NCT01839422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Description: Brain imaging examination : Structural and functional MRI to compare differences between each sample.
Study NCT00048672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Starting dose of 400 mg orally daily.
Study NCT03462394 — intervention group
Intervention type: OTHER
Intervention: Current Script
Description: This is the version of the phone call script currently used at NYU Langone Health.
Study NCT03462394 — intervention group
Intervention type: OTHER
Intervention: Alternate Script Iterations
Description: Intervention includes various iterations of the phone call script (different wording or script structure).
Study NCT02287584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DSP-5423P Placebo
Description: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
Study NCT02287584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P 40mg
Description: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
Study NCT02287584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P 80mg
Description: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
Study NCT02287584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P Placebo-to-Flex
Description: DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Study NCT02287584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P Active-to-Flex
Description: DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Study NCT06261983 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel node biopsy guided by magnetic probe
Description: Sentinel nodes exeresis guided by magnetic probe after injection submucosally and peritumorally of super-para-magnetic contrast. Standard neck dissection (levels I-II) were carry out after sentinel node biopsy
Study NCT01062113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS
Study NCT01062113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study NCT01605435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin Group 1
Description: The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Study NCT01062113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study NCT00637130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.0008%
Study NCT00637130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.001%
Study NCT00637130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.0012%
Study NCT00637130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAVATAN
Study NCT00637130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Study NCT00637130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT02438943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit
Description: An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
Study NCT01605435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin Group 2
Description: The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Study NCT02649244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Family Caregiver Training Program
Description: The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
Study NCT02708537 — intervention group
Intervention type: BIOLOGICAL
Intervention: PRGF in candidates for sperm donors
Description: PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
Study NCT02614742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SFX-01
Description: An intervention releasing sulforaphane.
Study NCT02614742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo otherwise identical to Active product
Study NCT02731651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open hysterectomy
Description: Hysterectomy with laparotomy incision.
Study NCT02731651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic assisted vaginal hysterectomy
Description: Hysterectomy with laparoscopic assisstance.
Study NCT00625417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast biopsy
Study NCT00625417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histopathologic examination
Study NCT00625417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light-scattering spectroscopy
Study NCT00625417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01762202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01762202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT01762202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Study NCT03137940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
Study NCT03137940 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
Study NCT00976976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, capecitabine, cisplatin
Description: Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
Study NCT02184273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium metamizol
Study NCT02184273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03919201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance band exercise intervention
Description: Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
Study NCT03919201 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No exercise intervention group
Description: Control group: no exercise intervention
Study NCT02520115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02520115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Analysis of serum and tissue samples
Study NCT03871205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen loaded DC vaccine
Description: Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
Study NCT03247153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Imaging of the heart using ultrasound
Study NCT02041117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
Study NCT01131143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Voice
Description: A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
Study NCT01131143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Voice
Description: A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
Study NCT02438943 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Audit
Description: An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
Study NCT01609647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
Study NCT01609647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
Study NCT02438943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Intervention
Description: Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
Study NCT02745613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8 weeks of combined exercise intervention
Description: The subjects will undergo an 8 week combined exercise intervention
Study NCT03533114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-258
Description: Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
Study NCT03533114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: pain
Description: Lower abdominal and low back pain was questioned. Pain intensity was evaluated with a 0 to 10 cm visual analog scale (VAS): 0 indicated no pain and 10 indicated the worst imaginable pain \[18\]. Pain that developed during the activity was also questioned and stated as pain+ activity. A higher score indicates a more severe pain.
Study NCT02520115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO
Study NCT00421122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Description: inhalation therapy
Study NCT00421122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide (Pulmicort)
Description: inhalation
Study NCT00421122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline sulfate (Bricasol)
Description: inhalation therapy
Study NCT00421122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbutaline sulfate (Bricasol)
Description: inhalation therapy
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: fatigue
Description: Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 completely disagree to 7 completely agree. A score of 4 or higher generally indicates severe fatigue.
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: anxiety
Description: The Spielberger State Trait Anxiety Inventory (STAI) was used to evaluate levels of anxiety. The state part of the STAI is a 20-item self-report inventory designed to measure state anxiety (current feelings of apprehension, worry, etc.). The STAI state scale is scored on four levels of anxiety intensity from 1 not at all to 4 very much and with a total score between 20 and 80. A higher total score indicates a more severe anxiety level.
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: position sense
Description: Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
Study NCT04408742 — intervention group
Intervention type: OTHER
Intervention: balance
Description: The Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used to measure limits of stability. The participants were asked to position themselves in a comfortable position on the platform and their foot position coordinate was recorded. The participants were asked to complete as quickly as possible the directional tasks displayed on a screen, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s. A total score was recorded. The higher the total score, the better the ability of the subjects to transfer the center of gravity.